Organization (Industry)
BIO PRODUCTS LABORATORY LIMITED
ClinicalTrials.gov lists BIO PRODUCTS LABORATORY LIMITED as lead sponsor of 27 trials. It has 6 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers BIO PRODUCTS LABORATORY LIMITED: 27 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (16)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Primary Immunodeficiency Diseases | 6 |
| Hemophilia A | 5 |
| Hemophilia B | 5 |
| Common Variable Immunodeficiency | 4 |
| Factor X Deficiency | 4 |
Showing 5 of 16 disease areas.
Trials by start year as sponsor or collaborator (16)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2018 | 1 |
| 2017 | 1 |
| 2015 | 2 |
| 2014 | 3 |
| 2013 | 1 |
| 2011 | 2 |
| 2010 | 1 |
| 2007 | 2 |
| 2006 | 2 |
| 2005 | 2 |
Showing 10 of 16 years.
Recruitment duration, a model prediction: none of the 27 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (6)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Immune Globulin | 4 |
| Vigam® (Human Normal Immunoglobulin) | 1 |
| Optivate 500IU | 1 |
| FACTOR X | 2 |
| Human Coagulation FACTOR X | 1 |
Showing 5 of 6 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 1 hit target (n=1) | 2 of 2 on time (n=2) |
Journals published in (4)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| PloS one | 3 |
| Allergy and asthma proceedings | 1 |
| Frontiers in immunology | 1 |
| Turkish journal of haematology : official journal of Turkish Society of Haematology | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 6 | 1 | 2021-10-19 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 6 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Bio Products Laboratory Ltd | Borehamwood, GB | FDA |
Organization relationships (2)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Isaac Melamed | Co sponsors trial with | 1 |
| BriovaRx Infusion Services | Co sponsors trial with | 1 |
Latest dated events (41)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2022-08-30 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2021-10-19 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2018-11-22 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2018-05-01 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2018-02-27 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 41 events.
Biomarker capability evidence (25)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CD4 | Trial sponsor | Named in trial inclusion criteria |
| CD40LG | Trial collaborator | Named in trial inclusion criteria |
| F10 | Trial sponsor | Named in trial inclusion criteria |
| F2 | Trial sponsor | Named in trial inclusion criteria |
| F2 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 25 evidence rows.
Biomarkers this organization publishes on (1)
| Biomarker | Publications |
|---|---|
| F10 | 1 |
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.